Video
Dr. Tutrone on phase 3 ARASENS data presented at Northeastern Section of the AUA
Author(s):
“What was found in the sub stratification study was that overall survival favored the addition of darolutamide to ADT and docetaxel in all stratification subgroups,” says Ronald Tutrone, MD, FACS, CPI.
Video Player is loading.
In this video, Ronald Tutrone, MD, FACS, CPI, discusses notable findings from the study, “Overall survival by stratification factors in the phase 3 ARASESNS study of darolutamide versus placebo in combination with androgen-deprivation therapy and docetaxel,” presented at the 74th Annual Meeting of the Northeastern Section of the American Urological Association. Tutrone is national medical director of clinical research for United Urology Group, Towson, Maryland.
Related Videos
How recombinant BCG could ease strain of supply issues
Suzanne B. Merrill, MD, FACS, on EAP program for recombinant BCG
Mark Edney, MD, highlights pending telehealth legislation
Gopa Iyer, MD, highlights findings from FORAGER-1 in metastatic urothelial carcinoma
Michael Schweizer, MD, shares data on mevrometostat plus enzalutamide in mCRPC
Laura Bukavina, MD, highlights study of urinary microbiome profiling
Kate Gessner, MD, on the mechanisms of immunotherapy failure in RCC
Darren Feldman, MD, on clinical outcomes in R/R testicular germ cell tumors
ASCO GU recap: Insights on 5 key trials
Laurence Albiges, MD, on COSMIC-313 trial of triplet vs doublet combination in aRCC
Related Content
February 19th 2025
